New drug combo aims to improve islet transplants for diabetics with kidney disease
NCT ID NCT07592000
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests a new drug called tegoprubart along with other medicines to help people with type 1 diabetes and chronic kidney disease receive pancreatic islet cell transplants. The goal is to see if this approach is safe and can improve blood sugar control without needing lifelong anti-rejection drugs like calcineurin inhibitors. Ten adults aged 18-70 will be followed for about 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that boosts red blood cells help anemia in kidney disease?
- Predicting kidney trouble in older adults: a data-driven approach to clearer lab results
- Could delaying kidney implant during heart transplant reduce complications?
- Can a new tablet formulation improve how a kidney disease drug is absorbed?
- New drug aims to reduce kidney damage in chronic disease
- Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients